Elenestinib clinical trials

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

This study is testing a new medicine, elenestinib, for a rare blood condition called indolent systemic mastocytosis. It compares the new medicine to a dummy pill (placebo) to see if it helps reduce symptoms that current treatments aren't fully controlling.